ArticleClinical and experimental gastroenterology2020
Cardiovascular Risk in Individuals with Inflammatory Bowel Disease.
Article in Clinical and experimental gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Systematic review with meta-analysis: effect of inflammatory bowel disease therapy on lipid levels.Alimentary pharmacology & therapeutics · 2021Pooled it
- Fecal microbiota transplantation mitigates cardiac remodeling and functional impairment in mice with chronic colitis.American journal of physiology. Gastrointestinal and liver physiology · 2026Article
- Article
- Oral Microbial Diversity is Associated with Biologic Treatment and Metabolic Health Status but not with Disease Activity in Patients with Inflammatory Bowel Disease.Crohn's & colitis 360 · 2025Article
- Cardiovascular Complications Are Increased in Inflammatory Bowel Disease: A Path Toward Achievement of a Personalized Risk Estimation.Journal of personalized medicine · 2025Article
- Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study.Inflammatory bowel diseases · 2025Article
- Non-Traditional Cardiovascular Risk Factors: Tailored Assessment and Clinical Implications.Journal of cardiovascular development and disease · 2025Review
- Targeting the Endocannabinoidome: A Novel Approach to Managing Extraintestinal Complications in Inflammatory Bowel Disease.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Cardiovascular disease: extraintestinal manifestation of inflammatory bowel disease.Intestinal research · 2025Review
- Review
- Inflammatory Bowel Disease and Cardiovascular Disease.Gastroenterology & hepatology · 2024Article
- Dietary Determinants of Metabolic and Gut Microbial Health in Patients with Inflammatory Bowel Disease.Nutrients · 2024Article
- Patient Demographics and Major Adverse Cardiovascular Events after Androgen Deprivation Therapy for Prostate Cancer.Advances in urology · 2024Article
- Cardiovascular manifestations of inflammatory bowel diseases and the underlying pathogenic mechanisms.American journal of physiology. Regulatory, integrative and comparative physiology · 2023Review
- Lipid Changes After Induction Therapy in Patients with Inflammatory Bowel Disease: Effect of Different Drug Classes and Inflammation.Inflammatory bowel diseases · 2023Article
- Vascular comorbidity is associated with decreased cognitive functioning in inflammatory bowel disease.Scientific reports · 2023Article
- Atherosclerotic cardiovascular diseases in inflammatory bowel diseases: to theFrontiers in cardiovascular medicine · 2023Review
- Antibiotics for the Secondary Prevention of Coronary Heart Disease.British journal of cardiac nursing · 2022Article
- Abdominal aortic calcification in patients with inflammatory bowel disease: does anti-tumor necrosis factor α use protect from chronic inflammation-induced atherosclerosis?Intestinal research · 2022Article
- Ischemic Heart Disease in Patients with Inflammatory Bowel Disease: Risk Factors, Mechanisms and Prevention.Life (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory bowel disease (IBD) patients present a higher risk of developing cardiovascular diseases due to the presence of chronic inflammation, which plays an essential role in atherogenesis. Therefore, the aim of the study was to evaluate the cardiovascular risk between patients with IBD and healthy control individuals. MATERIALS AND
methodsA total of 52 consecutive IBD outpatients from a tertiary hospital and 37 healthy controls were enrolled. Data collected included age, sex, smoking status, presence of comorbidities, disease activity, ongoing medical treatment, body mass index, arterial blood pressure, and cardiovascular risk. The cardiovascular risk was based on the Framingham risk score and ultrasonography variables, such as the carotid intima-media thickness and the presence of atherosclerotic plaque in the carotid. Multivariate logistic regression or multiple linear regression analysis was performed at a significance level of 5%.
resultsNo differences were observed between groups with regard to age, sex, smoking status, comorbidities, blood pressure, body mass index, lipid profile, and Framingham risk score. In the IBD group, fasting glucose [95 (86.2-107.3) mg/dL vs 86 (79-100) mg/dL, p=0.041], carotid intima-media thickness (0.69±0.12 mm vs 0.63±0.12 mm, p=0.031), and atherosclerotic carotid plaque (25% vs 5.4%, p=0.032) were higher compared with those in the control group. Multivariate logistic regression analysis showed that patients with IBD presented a 6.45-fold higher risk of carotid atherosclerotic plaque (odds ratio: 6.45; 95% confidence interval: 1.035-40.216; p<0.046).
conclusionPatients with IBD are at an increased risk of atherosclerosis and, consequently, an increased risk for cardiovascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.